Clinically significant interactions with antipsychotics

Mong Liang Lu, Hsien Yuan Lane

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Second-generation antipsychotics (SGAs) have become the mainstay of treatment for patients with schizophrenia and bipolar disorder. The antipsychotic drugs are often prescribed with other medications to improve clinical efficacy or treat comorbid diseases. Drug combinations can cause pharmacokinetic and/or pharmacodynamic drug-drug interactions. Pharmacokinetic interactions can occur during any pharmacokinetic phases, absorption, distribution, metabolism, or excretion. Smoking, caffeine, and food might have influences on the pharmacokinetic profiles of SGAs. Pharmacodynamic drug-drug interactions occur when drugs act at the same or interrelated sites of action, resulting in additive, synergistic, or antagonistic effects of each drug. Among the genes involved in pharmacokinetics, the members of cytochrome P450 family display large interindividual and interethnic variations in activity. Other enzyme systems such as UDP-glucuronosyltransferases also exhibit genetic polymorphism with potential clinical relevance in psychopharmacology. The demographic characteristics might also have impact on pharmacokinetic and/or pharmacodynamic profiles of SGAs. The potential pharmacokinetic interactions would guide antipsychotic dosage adjustments. For antipsychotics, optimal dose titration should be guided by measuring plasma concentrations. Therapeutic drug monitoring (TDM) is a valid tool for tailoring the dosage of antipsychotic drugs. Clinicians must have the knowledge of potential interactions of SGAs and carefully monitor patients to minimize potentially adverse events and maximize therapeutic efficacy.

Original languageEnglish
Title of host publicationApplied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents
PublisherSpringer International Publishing
Pages397-421
Number of pages25
ISBN (Electronic)9783319278834
ISBN (Print)9783319278810
DOIs
Publication statusPublished - Jan 1 2016

Fingerprint

Antipsychotic Agents
Pharmacokinetics
Drug Interactions
Pharmaceutical Preparations
Social Adjustment
Psychopharmacology
Glucuronosyltransferase
Drug Monitoring
Genetic Polymorphisms
Drug Combinations
Caffeine
Bipolar Disorder
Cytochrome P-450 Enzyme System
Schizophrenia
Smoking
Demography
Food
Enzymes
Therapeutics
Genes

Keywords

  • Absorption
  • Caffeine
  • Children and adolescent
  • Cytochrome P450 (CYP) enzymes
  • Distribution
  • Dosage adjustments
  • Elderly patients
  • Elimination
  • Metabolic disturbance
  • Metabolism pharmacodynamic
  • Pharmacokinetic
  • Pregnancy & breast-feeding
  • Smoking
  • Therapeutic drug monitoring (TDM)

ASJC Scopus subject areas

  • Medicine(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Lu, M. L., & Lane, H. Y. (2016). Clinically significant interactions with antipsychotics. In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents (pp. 397-421). Springer International Publishing. https://doi.org/10.1007/978-3-319-27883-4_16

Clinically significant interactions with antipsychotics. / Lu, Mong Liang; Lane, Hsien Yuan.

Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, 2016. p. 397-421.

Research output: Chapter in Book/Report/Conference proceedingChapter

Lu, ML & Lane, HY 2016, Clinically significant interactions with antipsychotics. in Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, pp. 397-421. https://doi.org/10.1007/978-3-319-27883-4_16
Lu ML, Lane HY. Clinically significant interactions with antipsychotics. In Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing. 2016. p. 397-421 https://doi.org/10.1007/978-3-319-27883-4_16
Lu, Mong Liang ; Lane, Hsien Yuan. / Clinically significant interactions with antipsychotics. Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents. Springer International Publishing, 2016. pp. 397-421
@inbook{d7e231d00e3d4eddae63c124090912fc,
title = "Clinically significant interactions with antipsychotics",
abstract = "Second-generation antipsychotics (SGAs) have become the mainstay of treatment for patients with schizophrenia and bipolar disorder. The antipsychotic drugs are often prescribed with other medications to improve clinical efficacy or treat comorbid diseases. Drug combinations can cause pharmacokinetic and/or pharmacodynamic drug-drug interactions. Pharmacokinetic interactions can occur during any pharmacokinetic phases, absorption, distribution, metabolism, or excretion. Smoking, caffeine, and food might have influences on the pharmacokinetic profiles of SGAs. Pharmacodynamic drug-drug interactions occur when drugs act at the same or interrelated sites of action, resulting in additive, synergistic, or antagonistic effects of each drug. Among the genes involved in pharmacokinetics, the members of cytochrome P450 family display large interindividual and interethnic variations in activity. Other enzyme systems such as UDP-glucuronosyltransferases also exhibit genetic polymorphism with potential clinical relevance in psychopharmacology. The demographic characteristics might also have impact on pharmacokinetic and/or pharmacodynamic profiles of SGAs. The potential pharmacokinetic interactions would guide antipsychotic dosage adjustments. For antipsychotics, optimal dose titration should be guided by measuring plasma concentrations. Therapeutic drug monitoring (TDM) is a valid tool for tailoring the dosage of antipsychotic drugs. Clinicians must have the knowledge of potential interactions of SGAs and carefully monitor patients to minimize potentially adverse events and maximize therapeutic efficacy.",
keywords = "Absorption, Caffeine, Children and adolescent, Cytochrome P450 (CYP) enzymes, Distribution, Dosage adjustments, Elderly patients, Elimination, Metabolic disturbance, Metabolism pharmacodynamic, Pharmacokinetic, Pregnancy & breast-feeding, Smoking, Therapeutic drug monitoring (TDM)",
author = "Lu, {Mong Liang} and Lane, {Hsien Yuan}",
year = "2016",
month = "1",
day = "1",
doi = "10.1007/978-3-319-27883-4_16",
language = "English",
isbn = "9783319278810",
pages = "397--421",
booktitle = "Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents",
publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Clinically significant interactions with antipsychotics

AU - Lu, Mong Liang

AU - Lane, Hsien Yuan

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Second-generation antipsychotics (SGAs) have become the mainstay of treatment for patients with schizophrenia and bipolar disorder. The antipsychotic drugs are often prescribed with other medications to improve clinical efficacy or treat comorbid diseases. Drug combinations can cause pharmacokinetic and/or pharmacodynamic drug-drug interactions. Pharmacokinetic interactions can occur during any pharmacokinetic phases, absorption, distribution, metabolism, or excretion. Smoking, caffeine, and food might have influences on the pharmacokinetic profiles of SGAs. Pharmacodynamic drug-drug interactions occur when drugs act at the same or interrelated sites of action, resulting in additive, synergistic, or antagonistic effects of each drug. Among the genes involved in pharmacokinetics, the members of cytochrome P450 family display large interindividual and interethnic variations in activity. Other enzyme systems such as UDP-glucuronosyltransferases also exhibit genetic polymorphism with potential clinical relevance in psychopharmacology. The demographic characteristics might also have impact on pharmacokinetic and/or pharmacodynamic profiles of SGAs. The potential pharmacokinetic interactions would guide antipsychotic dosage adjustments. For antipsychotics, optimal dose titration should be guided by measuring plasma concentrations. Therapeutic drug monitoring (TDM) is a valid tool for tailoring the dosage of antipsychotic drugs. Clinicians must have the knowledge of potential interactions of SGAs and carefully monitor patients to minimize potentially adverse events and maximize therapeutic efficacy.

AB - Second-generation antipsychotics (SGAs) have become the mainstay of treatment for patients with schizophrenia and bipolar disorder. The antipsychotic drugs are often prescribed with other medications to improve clinical efficacy or treat comorbid diseases. Drug combinations can cause pharmacokinetic and/or pharmacodynamic drug-drug interactions. Pharmacokinetic interactions can occur during any pharmacokinetic phases, absorption, distribution, metabolism, or excretion. Smoking, caffeine, and food might have influences on the pharmacokinetic profiles of SGAs. Pharmacodynamic drug-drug interactions occur when drugs act at the same or interrelated sites of action, resulting in additive, synergistic, or antagonistic effects of each drug. Among the genes involved in pharmacokinetics, the members of cytochrome P450 family display large interindividual and interethnic variations in activity. Other enzyme systems such as UDP-glucuronosyltransferases also exhibit genetic polymorphism with potential clinical relevance in psychopharmacology. The demographic characteristics might also have impact on pharmacokinetic and/or pharmacodynamic profiles of SGAs. The potential pharmacokinetic interactions would guide antipsychotic dosage adjustments. For antipsychotics, optimal dose titration should be guided by measuring plasma concentrations. Therapeutic drug monitoring (TDM) is a valid tool for tailoring the dosage of antipsychotic drugs. Clinicians must have the knowledge of potential interactions of SGAs and carefully monitor patients to minimize potentially adverse events and maximize therapeutic efficacy.

KW - Absorption

KW - Caffeine

KW - Children and adolescent

KW - Cytochrome P450 (CYP) enzymes

KW - Distribution

KW - Dosage adjustments

KW - Elderly patients

KW - Elimination

KW - Metabolic disturbance

KW - Metabolism pharmacodynamic

KW - Pharmacokinetic

KW - Pregnancy & breast-feeding

KW - Smoking

KW - Therapeutic drug monitoring (TDM)

UR - http://www.scopus.com/inward/record.url?scp=84978245388&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978245388&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-27883-4_16

DO - 10.1007/978-3-319-27883-4_16

M3 - Chapter

SN - 9783319278810

SP - 397

EP - 421

BT - Applied Clinical Pharmacokinetics and Pharmacodynamics of Psychopharmacological Agents

PB - Springer International Publishing

ER -